Top

Journal of Hepato-Biliary-Pancreatic Sciences

Published in:

01-11-2009 | Review article

Role of p38 and JNK in liver ischemia and reperfusion

Authors: LaShonda A. King, Alexander H. Toledo, Fernando A. Rivera-Chavez, Luis H. Toledo-Pereyra

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 6/2009

Abstract

Background/purpose

The signal transduction of mitogen-activated protein kinases (MAPKs) has appeared to be an important mediator of ischemic-related events. Because of this, we analyzed the participation of p38 and JNK in liver ischemia and reperfusion, as two individual members of the MAPK family of proteins.

Methods

All papers referred to in PubMed for the past 15 years were analyzed to determine how and when these MAPKs were considered to be an intricate part of the ischemic event. References were cross-studied to ascertain whether other papers could be found in the literature.

Results

The role of p38 and JNK in liver ischemia was confirmed in the literature. The activation of these mediators was associated with the induction of apoptosis and necrosis. Inhibitors of p38 and JNK reduced the liver ischemia and reperfusion damage, probably through the mechanisms mentioned before.

Conclusions

The development of effective inhibitors of p38 and JNK protein mediators is important for minimizing the harmful effects associated with liver ischemia and reperfusion.

Vardanian AJ, Busuttil RW, Kupiec-Weglinski JW. Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med. 2008;14:337–45.CrossRefPubMed

Cursio R, Filippa N, Miele C, Van Obberghen E, Gugenheim J. Involvement of protein kinase B and mitogen-activated protein kinases in experimental normothermic liver ischemia–reperfusion injury. Brit J Surg. 2006;93:752–61.CrossRefPubMed

Lopez-Neblina F, Toledo AH, Toledo-Peryra LH. Molecular biology of apoptosis in ischemia and reperfusion. J Invest Surg. 2005;18:335–50.CrossRefPubMed

Busuttil R. Liver ischemia and reperfusion injury. Brit J Surg. 2007;94:787–8.CrossRefPubMed

Kobayashi M, Takeyoshi I, Yoshinari D, Matsumoto K, Morishita Y. p38 mitogen-activated protein kinase inhibition attenuates ischemia–reperfusion injury of the rat liver. Surgery. 2002;131:344–9.CrossRefPubMed

Liang R, Nickkholgh A, Hoffmann K, Kern M, Schneider H, Sobirey M, et al. Melatonin protects from hepatic reperfusion injury through inhibition of IKK and JNK pathways and modification of cell proliferation. J Pineal Res. 2009;46:8–14.CrossRefPubMed

Toledo-Pereyra LH, Lopez-Neblina F, Toledo AH. Protein kinases in organ ischemia and reperfusion. J Invest Surg. 2008;21:215–26.CrossRefPubMed

Toledo-Pereyra LH, Toledo AH, Walsh J, Lopez-Neblina F. Molecular signaling pathways in ischemia/reperfusion. Exp Clin Transplant. 2004;2:174–7.PubMed

Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, Chan MH, et al. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol. 2005;175:7661–8.PubMed

10.

Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-α-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol. 2006;290:G583–9.CrossRefPubMed

11.

Shimizu OK, Tani T, Hashimoto T, Miwa K. JNK activation and apoptosis during ischemia–reperfusion. Transplant Proc. 1999;31:1077–9.CrossRefPubMed

12.

Kobayashi M, Takeyoshi I, Yoshinari D, Matsumoto K, Morishita Y. The role of mitogen-activated protein kinases and the participation of intestinal congestion in total hepatic ischemia–reperfusion injury. Hepatogastroenterology. 2006;53:243–8.PubMed

13.

Kumar S, Boehm J, Lee JC. p38 MAP Kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2:717–25.CrossRefPubMed

14.

Bradham CA, Stachlewitz RF, Gao W, Qian T, Jayadev S, Jenkins G, et al. Reperfusion after liver transplantation in rats differentially activates the mitogen-activated protein kinases. Hepatology. 1997;25:1128–35.CrossRefPubMed

15.

Yoshinari D, Takeyoshi I, Kobayashi M, Koyama T, Iijima K, Ohwada S, et al. Effects of a p38 mitogen-activated protein kinase inhibitor as an additive to University of Wisconsin solution on reperfusion injury in liver transplantation. Transplantation. 2001;72:22–7.CrossRefPubMed

16.

Massip-Salcedo M, Casillas-Ramirez A, Franco-Gou R, Bartrons R, Mosbah IB, Serafin A, et al. Heat shock proteins and mitogen-activated protein kinases in steatotic livers undergoing ischemia–reperfusion: some answers. Am J Pathol. 2006;168:1474–85.CrossRefPubMed

17.

Schnabl B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, Brenner DA. TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology. 2001;34:953–63.CrossRefPubMed

18.

Lopez-Neblina F, Toledo-Pereyra LH. Phosphoregulation of signal transduction pathways in ischemia and reperfusion. J Surg Res. 2006;134:292–9.CrossRefPubMed

19.

Teoh N, Pena AD, Farrell G. Hepatic ischemic preconditioning in mice is associated with activation of NF-κB, p38 kinase, and cell cycle entry. Hepatology. 2002;36:94–102.CrossRefPubMed

20.

Teoh N, Laclercq I, Pena AD, Farrell G. Low dose TNF-α protects against hepatic ischemia–reperfusion injury in mice: implications for preconditioning. Hepatology. 2003;37:118–28.CrossRefPubMed

21.

Interpro Database, European Bioinformatics Institute (2006–2009) http://www.ebi.ac.uk/interpro/Entry?ac=IPR008352.

22.

Kaminska B. MAPK signaling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefits. Biochem Biophys Acta. 2005;1754:253–62.PubMed

23.

Karin M. Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs. Ann Rheum Dis. 2004;63:ii62–4.CrossRefPubMed

24.

Keller M, Gerbes AL, Kulhanek-Heinze S, Gerwig T, Grutzner U, Van Rooijen N, et al. Hepatocyte cytoskeleton during ischemia and reperfusion—influence of ANP-mediated p38 MAPK activation. World J Gastroenterol. 2005;11:7418–29.PubMed

25.

Kiemer AK, Kulhanek-Heinze S, Gerwig T, Gerbes AL, Vollmar AM. Stimulation of p38 MAPK by hormonal preconditioning with atrial natriuretic peptide. World J Gastroenterol. 2002;8:707–11.PubMed

26.

Kobayashi K, Oshima K, Muraoka M, Akao T, Totsuka O, Shimizu H, et al. Effect of atrial natriuretic peptide on ischemia–reperfusion injury in a porcine total hepatic vascular exclusion model. World J Gastroenterol. 2007;13:3487–92.PubMed

27.

Bendinelli P, Piccoletti R, Maroni P, Bernelli-Zazzera A. The MAP kinase cascades are activated during post-ischemic liver reperfusion. FEBS Lett. 1996;398:193–7.CrossRefPubMed

28.

Lee KH, Kim SE, Lee YS. SP600125, a selective JNK inhibitor, aggravates hepatic ischemia–reperfusion injury. Exp Mol Med. 2006;38:408–16.PubMed

29.

Uehara T, Xi Peng X, Bennett B, Satoh Y, Friedman G, Currin R, et al. c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation. 2004;78:324–32.CrossRefPubMed

30.

Crenesse D, Gugenheim J, Hornoy J, Tornieri K, Laurens M, Cambien B, et al. Protein kinase activation by warm and cold hypoxia-regeneration in primary-cultured rat hepatocytes—JNK1/SAPK1 involvement in apoptosis. Hepatology. 2000;32:1029–36.CrossRefPubMed

31.

Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, Westwick JK, et al. JNK mediates hepatic ischemia reperfusion injury. J Hepatol. 2005;42:850–9.CrossRefPubMed

32.

Marderstein EL, Bucher B, Zhong Guo BS, Feng X, Reid K, Geller DA. Protection of rat hepatocytes from apoptosis by inhibition of c-Jun N-terminal kinase. Surgery. 2003;134:280–4.CrossRefPubMed

Title: Role of p38 and JNK in liver ischemia and reperfusion
Authors: LaShonda A. King
Alexander H. Toledo
Fernando A. Rivera-Chavez
Luis H. Toledo-Pereyra
Publication date: 01-11-2009
Publisher: Springer Japan
Published in: Journal of Hepato-Biliary-Pancreatic Sciences / Issue 6/2009
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI: https://doi.org/10.1007/s00534-009-0155-x

At a glance: The STEP trials

Springer Medicine

Role of p38 and JNK in liver ischemia and reperfusion

Abstract

Background/purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background/purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2009

Spleen and gastrosplenic ligament preserving distal pancreatectomy under a minimum incision approach assisted by laparoscopy

Evolution in techniques of laparoscopic pancreaticoduodenectomy: a decade long experience from a tertiary center

Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer?

Minimally invasive laparoscopic liver resection: 3D MDCT simulation for preoperative planning

In situ surgical procedures for locally advanced pancreatic cancer: partial abdominal evisceration and intestinal autotransplantation

Minimizing intraoperative bleeding using a vessel-sealing system and splenic hilum hanging maneuver in laparoscopic splenectomy